Results 121 to 130 of about 2,693 (166)

Efficacy and safety of imipenem/cilastatin/relebactam (IMI/CS/REL): a meta-analysis of randomized controlled clinical trials. [PDF]

BMC Infect Dis
Lei W, Duan Y, Xin M, Tian M, Xu J.
europepmc   +1 more source

Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel β-lactam/β-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. [PDF]

Microbiol Spectr
Kim TY, Baek JY, Suh E, Lee J-K, Yu H-J, Ko J-H, Huh HJ, Lee NY.   +7 more
europepmc   +1 more source

Multicenter Genomic Analysis of Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> in Austrian Community Hospitals Reveals Limited Carbapenemase Prevalence and Absence of Interhospital Clonal Spread. [PDF]

Antibiotics (Basel)
Diab-Elschahawi M, Kirk T, Häussler S, Presterl E, The Psps Working Group.   +4 more
europepmc   +1 more source

Molecular characterization of carbapenem-resistant Enterobacterales (CRE) and <i>in vitro</i> activity of novel beta lactams against CRE isolates from Malaysia. [PDF]

Microbiol Spectr
Rashid FA, Suhaila Che Hussin N, Anuar NFZ, Sahlan N, Palanisamy NK, Mohd Nor F.   +5 more
europepmc   +1 more source